MTOR and neuroendocrine neoplasm: In neuroendocrine tumors, mutations in Multiple endocrine neoplasia type 1 (MEN1), Death-domain associated protein (DAXX), and Alpha-thalassemia/mental retardation syndrome X-linked (ATRX), along with alterations in the Mammalian target of rapamycin (mTOR) pathway, have been linked to tumor biology and therapeutic response [16].